JP2013536855A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536855A5
JP2013536855A5 JP2013527250A JP2013527250A JP2013536855A5 JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5 JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5
Authority
JP
Japan
Prior art keywords
rarγ
use according
agonist
muscle tissue
myopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527250A
Other languages
English (en)
Other versions
JP2013536855A (ja
JP5986570B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/049905 external-priority patent/WO2012030919A2/en
Publication of JP2013536855A publication Critical patent/JP2013536855A/ja
Publication of JP2013536855A5 publication Critical patent/JP2013536855A5/ja
Application granted granted Critical
Publication of JP5986570B2 publication Critical patent/JP5986570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (19)

  1. 損傷した筋組織を有する対象において筋肉を修復または再生するための組成物において使用するためのレチノイン酸受容体γ（RARγ）アゴニストの使用であって、該RARγアゴニストがRARγ選択的アゴニストまたはRARγ/β選択的アゴニストである、前記使用。
  2. 損傷した筋組織が、身体の損傷または事故、疾患、感染、酷使、血液循環の喪失、または筋萎縮もしくは消耗の結果である、請求項1記載の使用。
  3. 損傷した筋組織が、ジストロフィー筋または加齢筋である、請求項1記載の使用。
  4. 損傷した筋組織が、筋萎縮／消耗の結果である、請求項1記載の使用。
  5. 損傷した筋組織が、ミオパシーの結果である、請求項1記載の使用。
  6. 筋肉を損傷させるミオパシーを有する対象において筋組織の損傷を低減させるための組成物において使用するためのレチノイン酸受容体γ（RARγ）アゴニストの使用であって、該RARγアゴニストがRARγ選択的アゴニストまたはRARγ/β選択的アゴニストである、前記使用。
  7. ミオパシーが炎症性ミオパシーである、請求項5または6記載の使用。
  8. ミオパシーが骨化性筋炎である、請求項5または6記載の使用。
  9. ミオパシーが筋ジストロフィーである、請求項5または6記載の使用。
  10. 対象が、骨格筋に対する損傷を有する、請求項5〜9のいずれか1項記載の使用。
  11. 投与が局所的または全身性である、請求項1〜10のいずれか1項記載の使用。
  12. 損傷した筋組織を負ったことに起因して対象において内因性のレチノイドシグナル伝達が増強している期間に投与を開始する、請求項1〜11のいずれか1項記載の使用。
  13. 損傷した筋組織を対象が負った後3日目より後に投与を開始する、請求項1〜10のいずれか1項記載の使用。
  14. RARγアゴニストがRARγ選択的アゴニストである、請求項1〜12のいずれか1項記載の使用。
  15. RARγ受容体に対するRARγ選択的アゴニストの結合親和性が、RARα受容体に対する結合親和性より少なくとも5倍高い、請求項14記載の使用。
  16. RARγ受容体に対するRARγ選択的アゴニストの結合親和性が、RARα受容体に対する結合親和性より少なくとも10倍高い、請求項15記載の使用。
  17. RARγアゴニストが、CD-271（6-(4-メトキシ-3-トリシクロ[3.3.1.13,7]デク-1-イルフェニル)-2-ナフタレンカルボン酸）；CD-394、CD-437（6-(4-ヒドロキシ-3-トリシクロ[3.3.1.13,7]デク-1-イルフェニル)-2-ナフタレンカルボン酸）；CD-1530（4-(6-ヒドロキシ-7-トリシクロ[3.3.1.13,7]デク-1-イル-2-ナフタレニル)安息香酸）；CD-2247;パロバロテン（4-[(E)-2-[5,6,7,8-テトラヒドロ-5,5,8,8-テトラメチル-3-(1H-ピラゾル-1-イルメチル)-2-ナフタレニル]-エテニル]-安息香酸）；BMS-270394（3-フルオロ-4-[(R)-2-ヒドロキシ-2-(5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロ-ナフタレン-2-イル)-アセチルアミノ]-安息香酸）;BMS-189961（3-フルオロ-4-[2-ヒドロキシ-2-(5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロ-ナフタレン-2-イル)-アセチルアミノ]-安息香酸）;CH-55（4-[(E)-3-(3,5-ジ-tert-ブチル-フェニル)-3-オキソ-プロペニル]-安息香酸）;6-[3-(アダマンタン-1-イル)-4-(プロプ-2-イニルオキシ)フェニル]ナフタレン-2-カルボン酸;5-[(E)-3-オキソ-3-(5,5,8,8-テトラヒドロナフタレン-2-イル)プロペニル]チオフェン-2-カルボン酸；ならびにそのエナンチオマー、誘導体、プロドラッグ、および薬学的に許容される塩からなる群より選択される、請求項1〜16のいずれか1項記載の使用。
  18. RARγアゴニストが、4-[(E)-2-[5,6,7,8-テトラヒドロ-5,5,8,8-テトラメチル-3-(1H-ピラゾル-1-イルメチル)-2-ナフタレニル]-エテニル]-安息香酸またはその薬学的に許容される塩である、請求項17記載の使用。
  19. 抗炎症剤と併用するための、請求項1〜18のいずれか1項記載の使用。
JP2013527250A 2010-09-01 2011-08-31 筋修復および再生のための組成物および方法 Active JP5986570B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01
US61/378,996 2010-09-01
PCT/US2011/049905 WO2012030919A2 (en) 2010-09-01 2011-08-31 Composition and method for muscle repair and regeneration

Publications (3)

Publication Number Publication Date
JP2013536855A JP2013536855A (ja) 2013-09-26
JP2013536855A5 true JP2013536855A5 (ja) 2014-10-16
JP5986570B2 JP5986570B2 (ja) 2016-09-06

Family

ID=45773490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527250A Active JP5986570B2 (ja) 2010-09-01 2011-08-31 筋修復および再生のための組成物および方法

Country Status (20)

Country Link
US (5) US9789074B2 (ja)
EP (3) EP4066826B1 (ja)
JP (1) JP5986570B2 (ja)
CN (2) CN103200937B (ja)
AU (1) AU2011296080B2 (ja)
BR (1) BR112013004685B1 (ja)
CA (1) CA2809374C (ja)
CL (1) CL2013000580A1 (ja)
CO (1) CO6680694A2 (ja)
DK (2) DK2613776T3 (ja)
EA (1) EA026251B1 (ja)
ES (3) ES2823234T3 (ja)
HU (2) HUE059024T2 (ja)
IL (1) IL224973B (ja)
MX (2) MX361414B (ja)
NZ (1) NZ607547A (ja)
PL (2) PL2613776T3 (ja)
PT (1) PT2613776T (ja)
WO (1) WO2012030919A2 (ja)
ZA (1) ZA201301536B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
CA2890424C (en) 2012-11-08 2020-11-17 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
US9375439B2 (en) 2013-01-09 2016-06-28 International Stem Cell Corporation Small molecules that promote skin regeneration
ES2694831T3 (es) 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
US11000057B2 (en) * 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
EP3091084A1 (en) 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
EP3411040A4 (en) * 2016-02-01 2020-07-29 President and Fellows of Harvard College SMALL MOLECULES FOR MASSATELLITE CELL POLLIFERATION
MX2018015108A (es) 2016-06-08 2019-08-29 Clementia Pharmaceuticals Inc Metodos para tratar la osificacion heterotopica.
AU2017359673B2 (en) 2016-11-16 2021-10-21 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (MO)
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
CN117244064A (zh) * 2022-06-16 2023-12-19 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1984003106A1 (en) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU7481098A (en) * 1997-05-13 1998-12-08 Case Western Reserve University Osteoarthritis cartilage regeneration using human mesenchymal stem ce lls
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
ATE368731T1 (de) 1998-05-29 2007-08-15 Osiris Therapeutics Inc Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
US6331570B1 (en) 1998-09-24 2001-12-18 Bristol-Myers Squibb Company Active enantiomer of RARγ-specific agonist
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
ATE328067T1 (de) 2000-04-28 2006-06-15 Childrens Medical Center Isolierung von mesenchymalen stammzellen und deren verwendung
DK1324970T3 (da) 2000-10-02 2009-01-05 Hoffmann La Roche Retinoider til behandling af emfysem
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002329276B2 (en) 2001-09-18 2008-04-24 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists I
KR100891224B1 (ko) 2001-09-18 2009-04-01 에프. 호프만-라 로슈 아게 치환된 우레아 레티노이드 작용제 ⅱ
AUPR892501A0 (en) * 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
WO2003101945A1 (en) * 2002-06-04 2003-12-11 Galderma Research & Development, S.N.C. Ligands that are inhibitors of the rar receptors
KR20050054907A (ko) * 2002-07-03 2005-06-10 폰다지오네 센트로 산 라파엘 델 몬테 테이보 조직 손상의 치료 및/또는 조직 회복의 촉진에서ｈｍｇｂ1 단백질의 용도
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
JP2005206544A (ja) * 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
AU2007210044A1 (en) 2006-01-26 2007-08-09 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
BRPI0709886A2 (pt) 2006-03-31 2011-07-26 Hoffmann La Roche processo para a preparaÇço de compostos retinàides
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2010088735A1 (en) * 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
WO2011011513A1 (en) 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2726084A1 (en) 2011-07-01 2014-05-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating pathologic heterotopic ossification
CA2865071C (en) 2012-02-22 2020-06-23 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
AU2013324396B2 (en) 2012-09-28 2018-10-04 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
ES2694831T3 (es) 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
JP2017536411A (ja) 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
MX2018015108A (es) 2016-06-08 2019-08-29 Clementia Pharmaceuticals Inc Metodos para tratar la osificacion heterotopica.
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Similar Documents

Publication Publication Date Title
JP2013536855A5 (ja)
JP2005522476A5 (ja)
Orfanos et al. Oral retinoids in the treatment of seborrhoea and acne
JP2009543799A5 (ja)
JP2008543854A5 (ja)
JP5654987B2 (ja) 日光角化症の処置のための局所用組成物
JP2008540394A5 (ja)
JP2009528296A5 (ja)
JP2013521286A5 (ja)
NZ607547A (en) Composition and method for muscle repair and regeneration
JP2007504212A5 (ja)
JP2005505545A5 (ja)
JP2017502073A5 (ja)
DK1507558T3 (da) Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
JP2014062126A5 (ja)
JP2008540050A (ja) 熱を印加して皮膚病変を治療するための治療装置および方法
JP2011507956A5 (ja)
JP2008512426A5 (ja)
JP2011529037A5 (ja)
JP2008537547A5 (ja)
AU2010320911B2 (en) Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
WO2007029760A1 (ja) 腸疾患の予防及び／又は治療のための医薬
JP2007505095A (ja) うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ
JP2018537503A5 (ja)
RU2020117569A (ru) Препарат для местного применения для лечения трихофитического онихомикоза